Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

Figures & data

Table 1 Age distribution of eligible cases

Age, years	n (%)
<55	39 (11.3%)
56–60	68 (19.7%)
61–70	136 (39.3%)
71–75	52 (15%)
>76	51 (14.7%)

Table 2 Characteristics of group A and group B

Characteristic	Group A	Group B
PSA, ng/mL	4–10	10–20
Mean age, years	64.38	68.5
Number of cases (%)	226 (65.3%)	120 (34.7%)

Abbreviation: PSA, prostate-specific antigen.

Table 3 Histopathology of biopsied cases

Group	Mean age (SD)	N	n (%)
			PCa	BPH	Prostatitis
Group A	64.4 (8.13)	226	115 (51%)	59 (26%)	52 (23%)
Group B	68.5 (8.5)	120	78 (65%)	21 (17.5%)	21 (17.5%)

Abbreviations: BPH, benign prostate hyperplasia; PCa, prostate cancer; SD, standard deviation.

Table 4 The relations between the pathologic diagnoses, age, PSA, and prostate volume

	Mean age (SD)^a	Mean PSA (SD)^b	Prostate volume^c
PCa	67.6 (8.9)	10.02 (4.37)	46 cm^3
BPH	64.5 (7.5)	8.4 (3.56)	74 cm^3
Prostatitis	62.3 (6.8)	8.7 (3.72)	64.67 cm^3

Notes:

a P = 0.01;

b P = 0.4;

c P = 0.01.

Abbreviations: BPH, benign prostate hyperplasia; PCa, prostate cancer; PSA, prostate-specific antigen; SD, standard deviation.